BNF:

Immune system and malignant disease

Status:

Red

Decision Date:

July 2016

Comments

RED:

• NICE TA395: for previously treated anaplastic lymphoma kinase positive non-small cell lung cancer.  (Decision date - July 2016).
• NICE TA500: for untreated ALK- positive non-small cell lung cancer.  (Decision date - February 2018).

NHS England drug.  To be used in line with NHSE commissioning intentions.

Red Drug Classifications

• 1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
• 2: Requiring long term on-going monitoring of efficacy by a specialist and not suitable for shared care
• 3: Requiring long term on-going monitoring of toxicity by a specialist (either because of difficulty in recognising side effects or high cost of investigations to identify toxicity)

search again